Enzo Biochem, Inc. 

(Public, NYSE:ENZ)   Watch this stock   
Find more results for ENZ
Nov 17, 2009
Lazard Capital Healthcare Conference
Oct 15, 2009
Q4 2009 Earnings Conference Call
Oct 14, 2009
Q4 2009 Earnings Release
Sep 21, 2009
UBS Global Life Sciences Conference
Sep 11, 2009
Thomas Weisel Partners Healthcare Conference
Sep 10, 2009
Rodman & Renshaw Annual Global Investment Conference
More events from AOL Finance »    

Key stats and ratios

Q3 (Jul '09) 2009
Net profit margin -21.52% -26.31%
Operating margin -21.87% -26.86%
EBITD margin - -22.18%
Return on average assets -15.64% -16.38%
Return on average equity -17.92% -18.48%
Employees 539 -

Address

527 Madison Avenue
New York, NY 10022
United States - Map
+1-212-5830100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com

Enzo Biochem, Inc. discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

Enzo Biochem, Inc. discussions

  View all discussions »

Description

Enzo Biochem, Inc. (Enzo) is a life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and on serving as a provider of diagnostic services to the medical community. The Company is engaged in research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally. The Company operates in three segments: Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. On March 12, 2009, the Company’s subsidiary Enzo Life Sciences, Inc. and Enzo Life Sciences Acquisition, Inc., a newly formed wholly owned subsidiary of Enzo Life Sciences, Inc. acquired Assay Designs, Inc.

Officers and directors

Elazar Rabbani Ph.D.
Chairman of the Board, Chief Executive Officer
Age: 64
Bio & Compensation - Reuters
Barry W. Weiner
President, Chief Financial Officer, Director
Age: 58
Bio & Compensation - Reuters
Carl W. Balezentis Ph.D.
President of Enzo Life Sciences, Inc.
Age: 51
Bio & Compensation - Reuters
Christine T. Fischette Ph.D.
President of Enzo Therapeutics, Inc.
Age: 57
Bio & Compensation - Reuters
Kevin Krenitsky M.D.
President of Enzo Clinical Labs
Bio & Compensation - Reuters
Andrew R. Crescenzo CPA
Senior Vice President - Finance
Age: 52
Bio & Compensation - Reuters
Herbert B. Bass
Vice President - Finance
Age: 60
Bio & Compensation - Reuters
David C. Goldberg
Vice President - Corporate Development; Senior Vice President of Enzo Clinical Labs, Inc.
Age: 51
Bio & Compensation - Reuters
Andrew P. Whiteley
Vice President - Business Development; Chief Operating Officer of Enzo Life Sciences, Inc.
Age: 50
Bio & Compensation - Reuters
Shahram K. Rabbani
Treasurer, Secretary, Director
Age: 56
Bio & Compensation - Reuters